Icon has brought its operations in line with new FDA guidelines by implementing an electronic system to accelerate the adjudication of cardiovascular events in diabetes trials.
Molecular Insight Pharmaceuticals is buying a commercial-scale
radiopharmaceutical manufacturing facility in Texas for $3m as it
moves towards increasing its manufacturing in the increasingly
profitable pharmaceutical area.
Pharma company NovaDel has announced that the US regulators have
given the thumbs up to its oral spray for relieving and preventing
angina due to coronary artery disease.
UK Biopharma company Evolutec has signed a deal with Wacker Biotech
to produce Evolutec's new autoimmune disease drug candidate rEV576
for clinical trials.
Covalent Group has signed a new contract worth $2.3 m (€1.9 m) to
conduct a global Phase 2 clinical trial of a new antithrombotic
agent in the US, Europe, and South America.
The latest research included in the proceedings of the annual
meeting of the European Society of Cardiology, (ESC) means that
heart treatments and management therapies feature strongly in
DrugResearcher's round-up of the 5-day...
A new study, which uses a new method in identifying the specific
gene involved in high cholesterol has been hailed as, "a landmark
publication." The study also describes the potential to use this
approach in forming a treatment...
There is no doubt that the introduction of stents, and latterly
those that deliver pharmacological agents, has revolutionised the
treatment of coronary artery disease over the last 10 years and all
but consigned heart surgery to second-line...
A naturally occurring protein, which promotes the ability to repair
heart muscle after a myocardial infarction, significantly reducing
cardiac damage, may have drug applications as a wound healing
treatment for the heart.